These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 21847635)
21. Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. Zhong W; Zhang Y; Zhang MZ; Huang XH; Li Y; Li R; Liu QW J Clin Pharm Ther; 2018 Jun; 43(3):414-421. PubMed ID: 29247451 [TBL] [Abstract][Full Text] [Related]
22. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Sasaki T; Tabuchi H; Higuchi S; Ieiri I Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670 [TBL] [Abstract][Full Text] [Related]
23. Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation. van Dijkman SC; De Cock PAJG; Smets K; Decaluwe W; Smits A; Allegaert K; Vande Walle J; De Paepe P; Della Pasqua O Eur J Clin Pharmacol; 2019 Oct; 75(10):1393-1404. PubMed ID: 31312867 [TBL] [Abstract][Full Text] [Related]
24. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428 [TBL] [Abstract][Full Text] [Related]
25. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling. Jaber MM; Brundage RC J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366 [TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and sedative effects of dexmedetomidine in dairy calves. Cagnardi P; Villa R; Ravasio G; Lucatello L; Di Cesare F; Capolongo F; Boccardo A; Pravettoni D N Z Vet J; 2017 Jan; 65(1):14-18. PubMed ID: 27643584 [TBL] [Abstract][Full Text] [Related]
29. Intranasal dexmedetomidine in healthy beagles: An echocardiographic and pharmacokinetic/pharmacodynamic study. Santangelo B; Harel M; Fourel I; Micieli F; Cataldi M; Segard-Weisse E; Portier K Vet J; 2019 Sep; 251():105346. PubMed ID: 31492384 [TBL] [Abstract][Full Text] [Related]
30. Statistical identifiability and convergence evaluation for nonlinear pharmacokinetic models with particle swarm optimization. Kim S; Li L Comput Methods Programs Biomed; 2014 Feb; 113(2):413-32. PubMed ID: 24216078 [TBL] [Abstract][Full Text] [Related]
31. Large inter-individual variability in pharmacokinetics of dexmedetomidine and its two major N-glucuronides in adult intensive care unit patients. Yang M; Tse AHW; Lee A; Joynt GM; Zuo Z J Pharm Biomed Anal; 2019 Oct; 175():112777. PubMed ID: 31362246 [TBL] [Abstract][Full Text] [Related]
33. A robust method for the assessment of average bioequivalence in the presence of outliers and skewness. Burger DA; Schall R; van der Merwe S Pharm Res; 2021 Oct; 38(10):1697-1709. PubMed ID: 34676489 [TBL] [Abstract][Full Text] [Related]
34. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. Chrysostomou C; Schulman SR; Herrera Castellanos M; Cofer BE; Mitra S; da Rocha MG; Wisemandle WA; Gramlich L J Pediatr; 2014 Feb; 164(2):276-82.e1-3. PubMed ID: 24238862 [TBL] [Abstract][Full Text] [Related]
35. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. Delavenne X; Dargaud Y; Ollier E; Négrier C Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808 [TBL] [Abstract][Full Text] [Related]
36. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations. Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic study of dexmedetomidine in elderly patients during spinal anesthesia. Kuang Y; Zhang RR; Pei Q; Tan HY; Guo CX; Huang J; Xiang YX; Ouyang W; Duan KM; Wang SY; Yang GP Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1005-14. PubMed ID: 26413731 [TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. Iirola T; Ihmsen H; Laitio R; Kentala E; Aantaa R; Kurvinen JP; Scheinin M; Schwilden H; Schüttler J; Olkkola KT Br J Anaesth; 2012 Mar; 108(3):460-8. PubMed ID: 22277665 [TBL] [Abstract][Full Text] [Related]
39. A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. Carlsson KC; van de Schootbrugge M; Eriksen HO; Moberg ER; Karlsson MO; Hoem NO Ther Drug Monit; 2009 Feb; 31(1):86-94. PubMed ID: 19077930 [TBL] [Abstract][Full Text] [Related]
40. A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction. Yu M; Kim S; Wang Z; Hall S; Li L J Biopharm Stat; 2008; 18(6):1063-83. PubMed ID: 18991108 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]